Strategies to Improve Disease and Treatment-Related Symptoms in Patients with Pancreatic Cancer
This interactive web activity provides an update on strategies for improving disease and treatment-related symptoms in patients with pancreatic cancer. The activity reviews methods for early identification and management of symptoms, complications, and treatment-emergent adverse events.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with pancreatic cancer.
Upon completion of this activity, participants will be better able to do the following:
- Describe the current guidelines and treatment options for patients with pancreatic cancer
- Develop strategies including modified dosing regimens to improve disease and treatment-related symptoms in patients with pancreatic cancer
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Fadi Braiteh, MD||
Consultant/Advisor: Amgen Inc., AstraZeneca/MedImmune, Boehringer Ingelheim International GmbH, Clovis Oncology, Eisai Co., Ltd, Eli Lilly and Company, Exelixis, Inc., Gilead, Incyte Corporation, Ipsen Pharma, Lexicon Pharmaceuticals, Inc, Merck Sharp & Dohme Corp., Pfizer Inc., F. Hoffmann-La Roche Ltd/Genentech, Inc., Taiho Oncology, Inc, Takeda Pharmaceutical Company Limited
Speakers’ Bureau: Amgen Inc., AstraZeneca/MedImmune, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eli Lilly and Company, Incyte Corporation, Ipsen Pharma, Merck Sharp & Dohme Corp., Puma Biotechnology, Inc., F. Hoffmann-La Roche Ltd/Genentech, Inc., Taiho Oncology, Inc, Takeda Pharmaceutical Company Limited
Sandy Breslow, Alison Kemp, Bernard M. Abrams, MD, Louis Settembrino, and Christina M. Ohnsman, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Ipsen Biopharmaceuticals, Inc
Jointly provided by the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC.
CME CREDIT (PHYSICIANS)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Catalyst Medical Education, LLC., and Ipsen Biopharmaceuticals, Inc do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
Release date: August 10, 2018
Expiration date: August 9, 2019